RBC Capital Maintains Sophia Genetics(SOPH.US) With Buy Rating, Maintains Target Price $7
RBC Capital Keeps Their Buy Rating on SOPHiA GENETICS (SOPH)
TD Cowen Maintains Sophia Genetics(SOPH.US) With Buy Rating
Sophia Genetics Analyst Ratings
RBC Capital Maintains Outperform on Sophia Genetics, Lowers Price Target to $7
Morgan Stanley Downgrades SOPHiA GENETICS to Equal Weight From Overweight, Adjusts Price Target to $5 From $10
Hold Rating on SOPHiA GENETICS Amidst Q2 Revenue Shortfall and Balanced Risk/Reward Outlook
RBC Capital Remains a Buy on SOPHiA GENETICS (SOPH)
TD Cowen Maintains Sophia Genetics(SOPH.US) With Buy Rating
TD Cowen Sticks to Their Buy Rating for SOPHiA GENETICS (SOPH)
Sophia Genetics Analyst Ratings
Guggenheim Initiates Coverage On Sophia Genetics With Buy Rating, Announces Price Target of $6
Analysts Offer Insights on Healthcare Companies: Inari Medical (NARI), Biogen (BIIB) and SOPHiA GENETICS (SOPH)
RBC Capital Remains a Buy on SOPHiA GENETICS (SOPH)
SOPHiA GENETICS (SOPH) Gets a Buy From RBC Capital
RBC Capital Sticks to Its Buy Rating for SOPHiA GENETICS (SOPH)
Sophia Genetics Analyst Ratings
RBC Capital Reiterates Outperform on Sophia Genetics, Maintains $8 Price Target
Analysts Offer Insights on Healthcare Companies: SOPHiA GENETICS (SOPH), Green Thumb Industries (OtherGTBIF) and Marinus (MRNS)
Buy Rating Affirmed for SOPHiA GENETICS Amid Growth and Market Expansion Potential